Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14872146 | 0.86 | KDM4E (0.56) | GAAMAPTMEN1KMT2AMAOB | |
| SCHEMBL6852267 | 0.79 | LMNA (0.43) | LMNAMAPTMEN1KMT2ANPC1 | |
| SCHEMBL6676853 | 0.78 | GAA (0.50) | GAAMAOBKDM4EALDH1A1GABRA1 | |
| SCHEMBL13140612 | 0.77 | MAPT (0.49) | LMNAMAPTMEN1KMT2AMAOB | |
| SCHEMBL25591566 | 0.77 | MAPT (0.62) | LMNAMAPTMEN1KMT2AMAOB | |
| SCHEMBL29703893 | 0.77 | MAPT (0.62) | LMNAMAPTMEN1KMT2AMAOB | |
| SCHEMBL6852324 | 0.76 | LMNA (0.43) | LMNAMAPTMEN1KMT2ANPC1 | |
| SCHEMBL9140591 | 0.76 | LMNA (0.48) | LMNAMAPTMEN1KMT2ANPC1 | |
| SCHEMBL3253036 | 0.76 | LMNA (0.59) | LMNAMAPTMEN1KMT2ANPC1 | |
| SCHEMBL25591564 | 0.76 | NPC1 (0.49) | LMNAF2RL3MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034873-B2 | Pyridazine and pyrrole compounds, processes for obtaining them and uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-05-19 | — | — | US | disclosed |
| EP-2295428-A2 | Linear pyridazine and pyrrolic compounds, methods of preparation and applications | Centre National de la Recherche Scientifique (CNRS) (FR) | 2011-03-16 | — | — | EP | disclosed |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. (FR) | 2010-01-07 | — | — | US | disclosed |
| WO-2008012441-A2 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012440-A2 | PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | PPOX, PNPO, PLPBP | LMNA 3500/4885GAA 3181/4885F2RL3 2043/4885 |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | PPOX, PNPO, PLPBP | LMNA 4332/4885GAA 3044/4885F2RL3 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.